From the Research
Cefdinir is an appropriate treatment for severe Haemophilus influenzae infection, with a recommended dosage of 300 mg twice daily or 600 mg once daily for 10 days in adults, and 14 mg/kg/day divided into two doses, not exceeding 600 mg daily, in children. The effectiveness of cefdinir against H. influenzae is attributed to its broad-spectrum activity as a third-generation cephalosporin, as noted in studies such as 1 and 2. These studies demonstrate cefdinir's stability to hydrolysis by commonly occurring beta-lactamases, which is crucial for its efficacy against beta-lactamase-producing strains of H. influenzae.
Key points to consider in the treatment of severe H. influenzae infection with cefdinir include:
- The importance of completing the full course of antibiotics to prevent recurrence and reduce the risk of antibiotic resistance, as emphasized in 3 and 4.
- The potential for alternative treatments, such as fluoroquinolones or macrolides, if there is concern about resistance or if the patient has a penicillin allergy, as discussed in 5.
- The need to monitor for adverse events, such as diarrhea, which is a common side effect of cefdinir, as reported in 1 and 2.
Overall, cefdinir is a viable option for the treatment of severe H. influenzae infection, offering a convenient once- or twice-daily dosing regimen and a broad spectrum of activity against common respiratory tract pathogens. However, it is essential to consider the patient's specific needs and potential contraindications when selecting an antibiotic regimen, as highlighted in 3 and 4.